tbuckley/cabot-search huggingface dataset:
MPTH-47. A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS OF SURVIVAL IN PATIENTS WITH ANAPLASTIC OLIGODENDROGLIOMA FROM 1996-2016
Authors: Nancy Ann Oberheim-Bush, Seunggu Han, Jennie Taylor, Jennifer Clarke, Susan Chang, Michael Prados, Mitchel S. Berger, Nicholas Butowski
Journal: Neuro-Oncology (2016)

Anaplastic oligodendrogliomas are a type of high grade glioma, a primary central nervous system neoplasm. Currently, there is no curative therapy, and median survival is estimated to be approximately 5 years. Until now, gliomas were categorized primarily through classic histologic methods, however, we now understand that molecular characterization of these tumors is a better predictor of survival. Furthermore, treatments vary from observation, to chemotherapy, radiation, or both in efforts to balance longevity with radiation toxicity. We performed a single institution retrospective analysis of the cases of anaplastic oligodendrogliomas at UCSF for the past 20 years and analysis of survival based on molecular characterization as well as treatments received is underway. There have been 159 cases of anaplastic oligodendrogliomas treated at UCSF from 1996-2016. The average age at diagnosis was 45.8 years with a range of 21-80. Forty-six percent of patients had an original diagnosis of anaplastic oligodendroglioma, while 53% had a transformation from a lower grade, of those 67% were originally diagnosed with a grade II oligodendroglioma. In 93 cases, IDH mutation status was tested; of those 90% were positive for the IDH1-R132H mutation and 2% were positive for an IDH2 mutation. In 120 cases, 1p19q deletion status was tested and 88.3% were found to have co-deletion of the 1p and 19q chromosomes. Treatments varied significantly with 34% of patients receiving radiation therapy with concurrent and adjuvant chemotherapy, 8% of patients receiving radiation with concurrent chemotherapy without adjuvant treatment, 32% receiving chemotherapy alone, 7% receiving radiation alone, and 5% undergoing imaging surveillance. Acquisition of survival data is on-going and updated results will be presented. This study will provide information regarding the survival of patients with anaplastic oligodendroglioma, and aims to help determine the most effective treatment options.
Toward Therapy of Human Prion Diseases
Authors: Adriano Aguzzi, Asvin K.K. Lakkaraju, Karl Frontzek
Journal: The Annual Review of Pharmacology and Toxicology (2017)

Three decades after the discovery of prions as the cause of Creutzfeldt-Jakob disease and other transmissible spongiform encephalopathies, we are still nowhere close to finding an effective therapy. Numerous pharmacological interventions have attempted to target various stages of disease progression, yet none has significantly ameliorated the course of disease. We still lack a mechanistic understanding of how the prions damage the brain, and this situation results in a dearth of validated pharmacological targets. In this review, we discuss the attempts to interfere with the replication of prions and to enhance their clearance. We also trace some of the possibilities to identify novel targets that may arise with increasing insights into prion biology.
Sustained Molecular Responses to Dasatanib (SPRYCEL®) in Patients with Philadelphia Chromosome-Positive (Ph(+)) Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase (LyBP) Chronic Myeloid Leukemia after Imatinib (IM) Failure: A Single-Center Experience.
Authors: Joerg Chromik, Heike Pfeifer, Lydia Wunderle, Nadine Schoch, Barbara Wassmann, Patrick Brueck, Ashwin Gollerkeri, Dieter Hoelzer, Oliver G. Ottmann
Journal: Blood (2006)
P08.44 Phase II study of hypofractionated radiation therapy with concomitant and adjuvant temozolomide following surgical resection for patients with newly diagnosed glioblastoma: preliminary evaluation
Authors: P. Navarria, F. Pessina, A. Ascolese, S. Tomatis, L. Bello, M. Simonelli, M. Riva, E. Lopci, A. Santoro, M. Scorsetti
Journal: Neuro-Oncology (2016)
A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.
Authors: Ranjana Advani, Sven De Vos, Stephen M. Ansell, Brad Kahl, Bruce D. Cheson, Nancy L. Bartlett, Richard R. Furman, Jane N. Winter, Henry Kaplan, David Dornan, Nancy Whiting, Jonathan Drachman, Andres Forero-Torres
Journal: Blood (2008)
GENT-20. THE ROLE OF MIR-128 AND POLYCOMB REPRESSOR COMPLEXES IN RADIATION INDUCED PRONEURAL TO MESENCHYMAL SUBTYPE TRANSITION IN GLIOBLASTOMA STEM CELLS
Authors: Arun Kumar Rooj, Franz Ricklefs, Agnieszka Bronisz, E. Antonio Chiocca, Jakub Godlewski
Journal: Neuro-Oncology (2016)

Glioblastoma multiforme is categorized into four subtypes (proneural (PN), neural, classical, and mesenchymal (MES)) based on transcriptome profiling. Proneural-to-mesenchymal transition (PMT) is associated not-only with concomitant up regulation of MES-specific markers and down regulation of PN-specific markers, but also with increased malignancy, tumor recurrence and worse prognosis, but the underlying mechanisms of PMT remains poorly comprehended. Aberrant expression and activity of microRNAs has been shown to play an important role in GBM initiation and progression. We have previously showed that expression of microRNA-128 is significantly down regulated in GBM and when re-introduced it diminishes self-renewal of GBM stem-like cells (GSCs) and sensitizes them to irradiation. We have also found that expression of miR-128 was significantly higher in PN GSCs compared to MES subtype. Here we demonstrated that multiple doses of ionizing radiation induced a robust and stable PMT in PN GSCs. Irradiation of PN GSCs significantly increased the expression of MES-specific gene signature (BCL2A1, CD44, WT-1, LYN, and MET) and concomitantly downregulated PN-specific gene expression markers (CD133, SOX2, NES, OLIG2, and NOTCH1). The expression of miR-128 was also significantly downregulated in PN GSCs after both multiple or single dose of radiation. As a tumor-suppressive microRNA, miR-128 inhibited the MES GSC-high expression of Bmi1 and Suz12, two components of Polycomb Repressor Complexes (PRC) 1 and 2, respectively. Both PRCs are associated with enhanced radio-resistance and we showed stable upregulation of PRCs in PN GSCs upon irradiation. We also showed that stable over-expression of miR-128 in MES GSCs conferred them more sensitivity to irradiation by downregulating the level of PRCs. Taken together, our results suggests that radiation-induced suppression of miR-128 levels was concomitant with PMT, most likely by targeting the level/activity of PRCs and their target genes in GBM and that replacement of miR-128 was capable of increase radio-sensitivity in MES GSCs.
Benzene-Induced Leukemogenesis: Irreversible Inhibition of PTPN2 and Subsequent STAT1 Signaling Alteration By the Hematotoxic Metabolite Benzoquinone
Authors: Romain Duval, Linh-Chi Bui, Cécile Mathieu, Emile Petit, Jean-Marie Dupret, Jan Cools, Fabien Guidez, Christine Chomienne, Fernando Rodrigues-Lima
Journal: Blood (2015)
Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.
Authors: David Avigan, Baldev Vasir, Zekui Wu, Lynne Uhl, Therese Desliva, Jacalyn Rosenblatt, James D. Levine, Robin Joyce, Ken Miller, Nikhil Munshi, Paul Richardson, Joann Proper, Nancy Gillombardo, Patty Forino, Marisa Villaroel, Ken Anderson, Donald Kufe
Journal: Blood (2004)
MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role
Authors: A. Pambuku, G. Lombardi, R. Bertorelle, L. Bellu, P. Fiduccia, M.P. Gradiman, A. Della Puppa, B. Franco, D. D'Avella, V. Zagonel
Journal: Annals of Oncology (2016)
Alterations of ADAMTS-13 Activity as a Common Indicator of the Endothelial Dysfunction Developing in Different Thrombotic Microangiopathies.
Authors: Maribel Diaz-Ricart, Marta Palomo, Carla Carbo, Arturo Pereira, Marc Pino, Miquel Lozano, Enric Carreras, Esteban Saperas, Carme Altisent, Jose Aznar-Salati, Gines Escolar
Journal: Blood (2006)
Treosulfan, Fludarabine, and Antithymocyte Globulin - A Low Toxicity Conditioning Regimen for Unrelated Donor - Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.
Authors: Jerzy Holowiecki, Sebastian Giebel, Jerzy Wojnar, Miroslaw Markiewicz, Aleksandra Holowiecka-Goral, Iwona Wylezol, Malgorzata Krawczyk-Kulis, Krzysztof Wozniczka
Journal: Blood (2006)
Assessing the Risks Associated with MRI in Patients with a Pacemaker or Defibrillator
Authors: Robert J. Russo, Heather S. Costa, Patricia D. Silva, Jeffrey L. Anderson, Aysha Arshad, Robert W.W. Biederman, Noel G. Boyle, Jennifer V. Frabizzio, Ulrika Birgersdotter-Green, Steven L. Higgins, Rachel Lampert, Christian E. Machado, Edward T. Martin, Andrew L. Rivard, Jason C. Rubenstein, Raymond H.M. Schaerf, Jennifer D. Schwartz, Dipan J. Shah, Gery F. Tomassoni, Gail T. Tominaga, Allison E. Tonkin, Seth Uretsky, Steven D. Wolff
Journal: New England Journal of Medicine (2017)

The presence of a cardiovascular implantable electronic device has long been a contraindication for the performance of magnetic resonance imaging (MRI). We established a prospective registry to determine the risks associated with MRI at a magnetic field strength of 1.5 tesla for patients who had a pacemaker or implantable cardioverter-defibrillator (ICD) that was "non-MRI-conditional" (i.e., not approved by the Food and Drug Administration for MRI scanning).Patients in the registry were referred for clinically indicated nonthoracic MRI at a field strength of 1.5 tesla. Devices were interrogated before and after MRI with the use of a standardized protocol and were appropriately reprogrammed before the scanning. The primary end points were death, generator or lead failure, induced arrhythmia, loss of capture, or electrical reset during the scanning. The secondary end points were changes in device settings.MRI was performed in 1000 cases in which patients had a pacemaker and in 500 cases in which patients had an ICD. No deaths, lead failures, losses of capture, or ventricular arrhythmias occurred during MRI. One ICD generator could not be interrogated after MRI and required immediate replacement; the device had not been appropriately programmed per protocol before the MRI. We observed six cases of self-terminating atrial fibrillation or flutter and six cases of partial electrical reset. Changes in lead impedance, pacing threshold, battery voltage, and P-wave and R-wave amplitude exceeded prespecified thresholds in a small number of cases. Repeat MRI was not associated with an increase in adverse events.In this study, device or lead failure did not occur in any patient with a non-MRI-conditional pacemaker or ICD who underwent clinically indicated nonthoracic MRI at 1.5 tesla, was appropriately screened, and had the device reprogrammed in accordance with the prespecified protocol. (Funded by St. Jude Medical and others; MagnaSafe ClinicalTrials.gov number, NCT00907361 .).
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Authors: Peter C. Taylor, Edward C. Keystone, Désirée van der Heijde, Michael E. Weinblatt, Liliana del Carmen Morales, Jaime Reyes Gonzaga, Sergey Yakushin, Taeko Ishii, Kahaku Emoto, Scott Beattie, Vipin Arora, Carol Gaich, Terence Rooney, Douglas Schlichting, William L. Macias, Stephanie de Bono, Yoshiya Tanaka
Journal: New England Journal of Medicine (2017)

Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with rheumatoid arthritis.We conducted a 52-week, phase 3, double-blind, placebo- and active-controlled trial in which 1307 patients with active rheumatoid arthritis who were receiving background therapy with methotrexate were randomly assigned to one of three regimens in a 3:3:2 ratio: placebo (switched to baricitinib after 24 weeks), 4 mg of baricitinib once daily, or 40 mg of adalimumab (an anti-tumor necrosis factor α monoclonal antibody) every other week. End-point measures evaluated after adjustment for multiplicity included 20% improvement according to the criteria of the American College of Rheumatology (ACR20 response) (the primary end point), the Disease Activity Score for 28 joints (DAS28), the Health Assessment Questionnaire-Disability Index, and the Simplified Disease Activity Index at week 12, as well as radiographic progression of joint damage as measured by the van der Heijde modification of the total Sharp score (mTSS) (range, 0 to 448, with higher scores indicating greater structural joint damage) at week 24.More patients had an ACR20 response at week 12 with baricitinib than with placebo (primary end point, 70% vs. 40%, P<0.001). All major secondary objectives were met, including inhibition of radiographic progression of joint damage, according to the mTSS at week 24 with baricitinib versus placebo (mean change from baseline, 0.41 vs. 0.90; P<0.001) and an increased ACR20 response rate at week 12 with baricitinib versus adalimumab (70% vs. 61%, P=0.014). Adverse events, including infections, were more frequent through week 24 with baricitinib and adalimumab than with placebo. Cancers were reported in five patients (two who received baricitinib and three who received placebo). Baricitinib was associated with reductions in neutrophil counts and increases in levels of creatinine and low-density lipoprotein cholesterol.In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab. (Funded by Eli Lilly and Incyte; ClinicalTrials.gov number, NCT01710358 .).
Pronostic Value of Pretransplant Echocardiography in Allogeneic Hematopoietic Cell Transplantation
Authors: Sarmiento Mauricio, Ildefonso Espigado, Rocio Parody, Francisco Marquez, Jose Falantes, Teresa Caballero, Cristina Calderon, Magdalena Carmona, Jose Lopez, Jose A. Perez-Simon
Journal: Blood (2015)
Hydroxyurea for Treatment of Sickle Cell Disease in Adults in Africa
Authors: Titilola S. Akingbola, Santosh L. Saraf, Binal N. Shah, Chinedu Anthony Ezekekwu, Omowunmi Sonubi, Lewis L. Hsu, Richard S. Cooper, Victor R. Gordeuk, Bamidele O. Tayo
Journal: Blood (2016)
Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.
Authors: Wanlong Ma, Xi Zhang, Iman Jilani, Zhong Zhang, Hagop Kantarjian, Srdan Verstovsek, Francis Giles, Susan O’Brien, Maher Albitar
Journal: Blood (2007)
Effect of Pre-Analytical Conditions On the Results of Thrombodynamics Assay
Authors: Natalia M. Dashkevich, Tatiana V. Vuimo, Anna N. Balandina, Ruzanna A. Ovsepyan, Natalia P. Soshitova, Elena A. Seregina, Stepan S. Surov, Elena N. Lipets, Mikhail A. Panteleev, Fazoil I Ataullakhanov, Claude Negrier
Journal: Blood (2012)
Detailed safety profile of the anti-PD-1 monoclonal antibody pembrolizumab in 78 consecutive patients (pts) with advanced melanoma
Authors: C. Boutros, E. Routier, C. Hua, M. Texier, C. Mateus, C. Libenciuc, M. Reigneau, N. Benannoune, S. Roy, E. Lanoy, J. Le Pavec, F.L. Ladurie, F. Carbonnel, O. Lambotte, H. Izzedine, A. Berdelou, S. Champiat, J.-C. Soria, A. Eggermont, C. Robert
Journal: Annals of Oncology (2016)
Incomplete resection rate of cold snare polypectomy: a prospective single-arm observational study
Authors: Noriko Matsuura, Yoji Takeuchi, Takeshi Yamashina, Takashi Ito, Kenji Aoi, Kengo Nagai, Takashi Kanesaka, Fumi Matsui, Mototsugu Fujii, Tomofumi Akasaka, Noboru Hanaoka, Koji Higashino, Yasuhiko Tomita, Yuri Ito, Ryu Ishihara, Hiroyasu Iishi, Noriya Uedo
Journal: Endoscopy (2017)

<b>Background and study aims</b> Cold snare polypectomy (CSP) is considered to be safe for the removal of subcentimeter colorectal polyps. This study aimed to determine the rate of incomplete CSP resection for subcentimeter neoplastic polyps at our center. <b>Patients and methods</b> Patients with small or diminutive adenomas (diameter 1 – 9 mm) were recruited to undergo CSP until no polyp was visible. After CSP, a 1 – 3 mm margin around the resection site was removed using endoscopic mucosal resection. The polyps and resection site marginal specimens were microscopically evaluated. Incomplete resection was defined as the presence of neoplastic tissue in the marginal specimen. We also calculated the frequency at which the polyp lateral margins could be assessed for completeness of resection. <b>Results</b> A total of 307 subcentimeter neoplastic polyps were removed from 120 patients. The incomplete resection rate was 3.9 % (95 % confidence interval [CI] 1.7 % – 6.1 %); incomplete resection was not associated with polyp size, location, morphology, or operator experience. The polyp lateral margins could not be assessed adequately for 206 polyps (67.1 %). Interobserver agreement between incomplete resection and lateral polyp margins that were inadequate for assessment was poor (κ = 0.029, 95 %CI 0 – 0.04). Female sex was an independent risk factor for incomplete resection (odds ratio 4.41, 95 %CI 1.26 – 15.48; <i>P </i> = 0.02). <b>Conclusions</b> At our center, CSP resection was associated with a moderate rate of incomplete resection, which was not associated with polyp characteristics. However, adequate evaluation of resection may not be routinely possible using the lateral margin from subcentimeter polyps that were removed using CSP. Trial registered at University Hospital Medical Information Network (UMIN 000010879).
The STAR score predicts prognosis in Luminal-like breast cancer patients independently from dose-dense adjuvant chemotherapy
Authors: C. Fontanella, L. Del Mastro, S. De Placido, M. De Laurentiis, C. Boni, C. Giovanna, A. Durando, A. Turletti, A. Turletti, C. Nisticò, E. Valle, O. Garrone, F. Montemurro, S. Barni, A. Ardizzoni, T. Gamucci, G. Colantuoni, C. Bighin, F. Cognetti, F. Puglisi
Journal: Annals of Oncology (2016)
Leukemia Specific Complement Dependent Cytotoxicity Contributes to Anti-Leukemia Immunity Induced by Leukemia Cell-Derived HSP70 Immunization in Mice.
Authors: Junko Jimbo, Kazuya Sato, Takaaki Hosoki, Motohiro Shindo, Katsuya Ikuta, Yoshihiro Torimoto, Yutaka Kohgo
Journal: Blood (2005)
Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor.
Authors: Jan Walewski, Ewa Paszkiewicz-Kozik, Gabriela Borsaru, Andreea Moicean, Agnieszka Warszewska, Klaus Strobel, Alberto Biggi, Bernhard Hauns, Anna Mais, Stefan W. Henning, Bernd Hentsch
Journal: Blood (2010)
Post-marketing surveillance of all patients treated with sorafenib for unresectable DTC in Japan: Interim report
Authors: Makoto Tahara, Iwao Sugitani, Yasuhiro Ito, Yutaka Okayama, Yoshiko Kawakami, Toshiyuki Sunaya, Toshiaki Sakaguchi, Hironobu Minami, Tsuneo Imai
Journal: Annals of Oncology (2016)
SURG-36. IMPACT OF MULTIMODALITY MONITORING USING DIRECT ELECTRICAL STIMULATION TO DETERMINE CORTICOSPINAL TRACT SHIFT AND INTEGRITY IN THE iMRI suite
Authors: Daria Krivosheya, Ganesh Rao, Sudhakar Tummala, Vinodh Kumar, Dima Suki, Sujit Prabhu
Journal: Neuro-Oncology (2016)

Preserving the integrity of the corticospinal tract (CST) while maximizing the extent of tumor resection is one of the key principles of brain tumor surgery to prevent new neurological deficits. The goal of this project was to determine the impact of the use of peri-operative DTI fiber-tracking protocols for localization of the CSTs, in conjunction with intraoperative direct electrical stimulation (DES) on patient neurological outcomes. Fifty-three patients underwent resection of tumors adjacent to the motor gyrus and the underlying CST. Preoperative and postoperative DTI mapping, intraoperative cortical and subcortical direct electrical stimulation (DES) were performed in all patients. Eighteen patients (34%) had a re-resection after the first intraoperative scan. In the immediate postoperative period, 55% of patients developed a new neurological deficit. At the three-month follow up, however, only 6 patients (11%) had a persistent neurological deficit that was worse than the preoperative state. The proximity of the tumor to the CSTs was determined from preoperative studies. Tumor location further than 15 mm from CSTs correlated with better neurological outcomes at one and three months postoperatively (p=0.001 and 0.007 respectively) despite achieving a similar degree of resection (p=0.61). The current of subcortical DES performed with monopolar probe showed a linear correlation with the distance to the CST (R=1.10+/-0.83). Intraoperative imaging demonstrated that CST shifts on average (4.4+/-3.2) mm, but the direction of the shift is unpredictable. Resection of tumor tissue closer than 5 mm to the CST is associated with increased morbidity. In summary, a combination of DTI imaging, subcortical DES, and continuous motor evoked potential (CMEP) monitoring can be used in the iMRI suite to maximize tumor resection and preserve patient neurological function.
Transcriptomic signatures shaped by cell proportions shed light on comparative developmental biology
Authors: Sophie Pantalacci, Laurent Guéguen, Coraline Petit, Anne Lambert, Renata Peterkovà, Marie Sémon
Journal: Genome biology (2017)

Comparative transcriptomics can answer many questions in developmental and evolutionary developmental biology. Most transcriptomic studies start by showing global patterns of variation in transcriptomes that differ between species or organs through developmental time. However, little is known about the kinds of expression differences that shape these patterns. We compared transcriptomes during the development of two morphologically distinct serial organs, the upper and lower first molars of the mouse. We found that these two types of teeth largely share the same gene expression dynamics but that three major transcriptomic signatures distinguish them, all of which are shaped by differences in the relative abundance of different cell types. First, lower/upper molar differences are maintained throughout morphogenesis and stem from differences in the relative abundance of mesenchyme and from constant differences in gene expression within tissues. Second, there are clear time-shift differences in the transcriptomes of the two molars related to cusp tissue abundance. Third, the transcriptomes differ most during early-mid crown morphogenesis, corresponding to exaggerated morphogenetic processes in the upper molar involving fewer mitotic cells but more migrating cells. From these findings, we formulate hypotheses about the mechanisms enabling the two molars to reach different phenotypes. We also successfully applied our approach to forelimb and hindlimb development. Gene expression in a complex tissue reflects not only transcriptional regulation but also abundance of different cell types. This knowledge provides valuable insights into the cellular processes underpinning differences in organ development. Our approach should be applicable to most comparative developmental contexts.